WO2013019731A3 - Phosphate prodrugs - Google Patents

Phosphate prodrugs Download PDF

Info

Publication number
WO2013019731A3
WO2013019731A3 PCT/US2012/048857 US2012048857W WO2013019731A3 WO 2013019731 A3 WO2013019731 A3 WO 2013019731A3 US 2012048857 W US2012048857 W US 2012048857W WO 2013019731 A3 WO2013019731 A3 WO 2013019731A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphate prodrugs
prodrugs
phosphate
useful
compound
Prior art date
Application number
PCT/US2012/048857
Other languages
French (fr)
Other versions
WO2013019731A2 (en
Inventor
Tue Nguyen
Eugenio L. De Hostos
Original Assignee
Institute For Oneworld Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute For Oneworld Health filed Critical Institute For Oneworld Health
Publication of WO2013019731A2 publication Critical patent/WO2013019731A2/en
Publication of WO2013019731A3 publication Critical patent/WO2013019731A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C07F9/65306—Five-membered rings containing two nitrogen atoms
    • C07F9/65318—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65395—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of formula: wherein R1, L A, R, and n are defined herein, is useful for treating various disorders, including diarrhea.
PCT/US2012/048857 2011-08-01 2012-07-30 Phosphate prodrugs WO2013019731A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513917P 2011-08-01 2011-08-01
US61/513,917 2011-08-01

Publications (2)

Publication Number Publication Date
WO2013019731A2 WO2013019731A2 (en) 2013-02-07
WO2013019731A3 true WO2013019731A3 (en) 2013-08-01

Family

ID=47629871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048857 WO2013019731A2 (en) 2011-08-01 2012-07-30 Phosphate prodrugs

Country Status (1)

Country Link
WO (1) WO2013019731A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264471A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazole Derivatives
US20090318429A1 (en) * 2008-04-28 2009-12-24 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264471A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazole Derivatives
US20090318429A1 (en) * 2008-04-28 2009-12-24 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives

Also Published As

Publication number Publication date
WO2013019731A2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
NZ741985A (en) Prodrugs of fumarates and their use in treating various diseases
MX339873B (en) Serine/threonine kinase inhibitors.
WO2012122011A3 (en) Amino-quinolines as kinase inhibitors
PH12015501677A1 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
MX340756B (en) Quinazoline compounds as serine/threonine kinase inhibitors.
WO2014052563A3 (en) Novel compounds that are erk inhibitors
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
MX2012015252A (en) Sgc stimulators.
PH12015501755A1 (en) Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
WO2012096832A3 (en) Hdac inhibiting derivatives of camptothecin
WO2011123946A8 (en) Kinase inhibitors and method of treating cancer with same
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
MX2014002208A (en) Serine/threonine pak1 inhibitors.
EP2566477A4 (en) Amino-quinolines as kinase inhibitors
MX2014006018A (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines.
MX345780B (en) Tricyclic gyrase inhibitors.
CR20140495A (en) 5-AMINO [1,4] THIAZINES AS INHIBITORS OF BACE1
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
MY169028A (en) Process for making hydroxylated cyclopentylpyrimidine compounds
MX2013008371A (en) Methods of making hiv attachment inhibitor prodrug compound and intermediates.
MX348148B (en) Method for promoting plant growth.
WO2013062964A3 (en) Methanol derivatives as trpv3 modulators
MX359399B (en) 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS.
PH12014502747A1 (en) Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12820673

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12820673

Country of ref document: EP

Kind code of ref document: A2